bioecon Member area
Technology · Bioproduction & equipment / Cleanroom & facilities

Cryogenic equipment for biotech

Liquid-nitrogen storage tanks, controlled-rate freezers and cryogenic shipping systems that preserve cell/gene therapies, biospecimens and other biological materials at ultra-low temperature across manufacturing, storage and distribution, sold by dedicated cryogenic equipment and logistics providers.

Manufacturing Integration & TICs Risk: low Bioprocess equipment US · CN · EU Science: why it works → verified 2026-08-11 · 4 Sources (0 independent)

1 · What it gives

Cryogenic equipment maintains biological materials — cell and gene therapy products, cord blood, biospecimens, master and working cell banks — at temperatures cold enough to suspend biological activity, typically below -150°C using liquid nitrogen (LN2) vapor or liquid phase, or -80°C for ultra-low mechanical freezers. The category spans three distinct hardware classes: controlled-rate freezers that ramp temperature down at a programmed rate to protect cell viability during the freeze itself, isothermal or LN2-jacketed storage tanks that hold frozen product at stable temperature for long-duration storage, and cryogenic shipping systems (dry-vapor shippers) that maintain temperature during transport without the spill and pressure risks of liquid-phase LN2. A single cell or gene therapy product typically passes through all three equipment classes across its manufacturing-to-patient journey, with a validated chain-of-custody and temperature-excursion record required at every handoff.

The key directions of cryogenic equipment for biotech are:

  1. Controlled-rate freezing: programmable freezers that ramp temperature down at a validated rate (commonly 1°C/minute) to minimize ice-crystal damage and preserve cell viability during the freeze step itself.
  2. LN2-jacketed and isothermal storage tanks: long-duration storage vessels that hold frozen product at stable cryogenic temperature, ranging from small lab tanks to high-capacity biorepository installations.
  3. Cryogenic shipping systems: dry-vapor shippers that absorb liquid nitrogen into a porous matrix, maintaining cryogenic temperature during transport without free liquid phase, the standard for cell and gene therapy distribution logistics.
  4. Temperature-monitoring and chain-of-custody software: connected sensors and tracking platforms that log temperature continuously and flag excursions across every handoff from manufacturing through patient administration.

Sectoral value chain#

[Cell/gene therapy product, biospecimen] ──> [Controlled-rate freezing]
                                                        │
                                              (validated freeze curve)
                                                        │
                                                        ▼
[Patient/end-use site] <─── [Cryogenic shipping] <─── [LN2 storage tank / biorepository]

Value chain levels#

LevelDescriptionKey inputs/outputs
Controlled-rate freezingA programmable freezer ramps temperature down at a validated rate, protecting cell viability during the transition from liquid to frozen state.In: unfrozen cell/gene therapy product or biospecimen. Out: frozen product at target storage temperature.
Cryogenic storageLN2-jacketed or isothermal tanks hold frozen product at stable cryogenic temperature for long-duration storage.In: frozen product. Out: stored product, continuously temperature-logged.
Cryogenic shippingDry-vapor shippers maintain cryogenic temperature during transport without free liquid-phase nitrogen.In: stored frozen product. Out: product in transit, temperature-validated for the shipping duration.
Chain-of-custody trackingConnected temperature sensors and tracking software log continuous temperature data and flag excursions at every handoff.In: product in transit or storage. Out: chain-of-custody record, excursion alerts.
Receipt and thawThe end-use site (clinic, manufacturing facility) receives and thaws the product under a validated protocol matched to its cryopreservation method.In: received frozen product. Out: thawed, patient-ready or process-ready product.
GMP documentationTemperature records, chain-of-custody logs and excursion reports are compiled against a validated protocol for regulatory release.In: monitoring data. Out: GMP-compliant storage and shipping record.

Cross-cutting technologies of the sector:

  • Dry-vapor shipping technology: a porous absorbent matrix holds liquid nitrogen in place, maintaining cryogenic vapor-phase temperature during transport without the pressure and spill risk of free liquid nitrogen.
  • Multi-probe temperature monitoring: controlled-rate freezers with multiple independent temperature probes validate that the freeze curve is uniform across the full sample load, not just at a single reference point.
  • Connected chain-of-custody platforms: cloud-linked temperature loggers provide continuous, auditable temperature records across every handoff from manufacturing through patient administration, a requirement increasingly specified for cell and gene therapy distribution.

2 · What it replaces 3 · matched by industry

3 · How to implement 6 steps

  1. 1
    Controlled-rate freezing
    A programmable freezer ramps the product’s temperature down at a validated rate, protecting cell viability during the transition from liquid to frozen state.
  2. 2
    Cryogenic storage
    LN2-jacketed or isothermal tanks hold the frozen product at stable cryogenic temperature for long-duration storage, continuously temperature-logged.
  3. 3
    Cryogenic shipping
    A dry-vapor shipper maintains cryogenic temperature during transport without free liquid-phase nitrogen, validated for the shipping duration.
  4. 4
    Chain-of-custody tracking
    Connected temperature sensors and tracking software log continuous data and flag any excursion at every handoff from manufacturing through patient administration.
  5. 5
    Receipt and thaw
    The end-use site receives and thaws the product under a validated protocol matched to its cryopreservation method.
  6. 6
    GMP documentationRegulatory & certification

    Temperature records, chain-of-custody logs and excursion reports are compiled against a validated protocol under 21 CFR Part 210/211 and EU GMP Annex 1 for regulatory release.


    Registration in Russia / EAEU: EAC — EAEU accredited bodies / Rosakkreditatsiya

4 · Who delivers

Matched suppliers (matched automatically)

Cryoport SystemsUnited StatesProduceractive
Kenya Animal Genetic Resources CentreKenyaProduceractive
Paul Mueller CompanyUnited StatesEquipmentactive
Kheiron BiotechArgentinaServices / consultingactive
Biogenic ApSDenmarkProduceractive
Paris Biofoundry (France)FranceResearch / RTOactive
BIONETSpainEquipmentactive
EnvirotainerSwedenProduceractive
DanaherUnited StatesProduceractive
Lonza GroupSwitzerlandProduceractive
PBS BiotechUnited StatesEquipmentactive

In the services and supply catalogue 2 · paid service

Cleanrooms & process utilities · Engineering, EPC & validation

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Chart Industries (MVE)🇺🇸 USAMVE 616, MVE HE series with CryoVerse ConnectWidely specified biological LN2 storage standard; automated fill/gas-bypass controlCommercial, public (NYSE: GTLS)
Cryoport🇺🇸 USACryoport Express, Cryomax shipping systemsReference dry-vapor cryogenic shipping platform for cell/gene therapy logisticsCommercial, public (NASDAQ: CYRX)
Worthington Industries (Taylor-Wharton)🇺🇸 USATaylor-Wharton LABS, VHC cryo storage tanksLong-established, widely distributed cryogenic tank brandCommercial, public (NYSE: WOR)
Custom Biogenic Systems🇺🇸 USAControlled-rate freezers, isothermal LN2 freezersMulti-probe freeze-curve monitoring; covers freeze and storage steps from one vendorCommercial

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

The US hosts the category’s leading cryogenic hardware manufacturers and the dominant cryogenic logistics provider serving the world’s largest cell and gene therapy manufacturing and clinical distribution base.

cryogenic storage hardware leadership, dry-vapor shipping logistics dominance#

  • Chart Industries (MVE brand): the MVE 616 wide-neck cylindrical biological LN2 storage tank and the MVE HE series with CryoVerse Connect controller and automated fill/gas-bypass functions are distributed through biomedical equipment resellers, a widely specified biological LN2 storage standard.
  • Custom Biogenic Systems: manufactures both controlled-rate freezers with multi-probe monitoring and isothermal LN2-jacketed freezers, covering the freeze and long-duration storage steps of the pipeline from a single vendor.
  • Cryoport: the Cryoport Express and Cryomax cryogenic shipping systems are the reference dry-vapor shipping platforms for life-sciences supply chains, specifically positioned for cell and gene therapy distribution logistics.
  • Worthington Industries (Taylor-Wharton brand): the Taylor-Wharton LABS and VHC cryo storage tank lines are widely distributed through laboratory and biomedical equipment resellers, a long-established cryogenic tank brand.

European Union

No EU-headquartered vendor cleared this screening round; the category is dominated by US-headquartered cryogenic hardware and logistics providers whose global platforms (Chart/MVE, Cryoport, Taylor-Wharton) are also the reference standard specified across European cell and gene therapy manufacturing.

global US brand specification, distributor-served European demand#

  • Global brand specification: European cell and gene therapy manufacturers specify the same MVE, Custom Biogenic Systems, Cryoport and Taylor-Wharton equipment lines sold in the US market, distributed through European biomedical equipment channels.
  • Screening note: the region-specific search did not surface a distinct EU-headquartered cryogenic equipment originator with confirmed evidence in this round — not asserted as absent, only as unconfirmed.

China

No China-headquartered cryogenic equipment maker cleared this screening round with confirmed, on-domain evidence; demand is driven by China’s expanding cell and gene therapy manufacturing and biobanking base, currently served largely through global vendors’ regional distribution networks.

import- and distributor-served market, domestic cell/gene therapy build-out#

  • Global vendor distribution: Chart Industries, Cryoport and other global cryogenic equipment and logistics providers maintain China distribution channels serving domestic cell and gene therapy manufacturing and biobanking.
  • Domestic cell/gene therapy build-out: China’s growing cell and gene therapy manufacturing base is the main demand driver for cryogenic storage and shipping capacity, without a confirmed domestic cryogenic-equipment originator identified in this screen.
  • Screening note: one candidate China-headquartered cryogenic equipment maker was probed and did not return confirming, on-domain evidence this round — not asserted as absent, only as unconfirmed.

6 · Money: tenders & grants

7 · Tech stack & innovations

The stack layers programmable freeze-curve control, cryogenic storage engineering and dry-vapor shipping technology on a common temperature-monitoring and chain-of-custody backbone.

  1. Programmable controlled-rate freezing:
    • Freezers ramp temperature down at a validated rate (commonly around 1°C/minute) to minimize ice-crystal formation and preserve cell viability during the freeze transition.
    • Multi-probe monitoring validates that the freeze curve is uniform across the full sample load rather than only at a single reference point, a requirement for GMP-documented cell therapy freezing.
  2. LN2-jacketed and automated-fill storage tanks:
    • Isothermal, LN2-jacketed tank designs hold stored product at stable cryogenic temperature with minimized liquid-nitrogen consumption versus open liquid-phase storage.
    • Automated fill and gas-bypass controllers maintain tank LN2 level without manual intervention, reducing the risk of a temperature excursion from a missed refill.
  3. Dry-vapor cryogenic shipping:
    • A porous absorbent matrix holds liquid nitrogen in place, maintaining cryogenic vapor-phase temperature during transport without the pressure and spill risk of free liquid-phase nitrogen.
    • Connected chain-of-custody platforms log continuous, auditable temperature data across every handoff from manufacturing through patient administration.

Sources 4 · 0 independent · 4 producer sites

Producers' own sites 4

  1. Chart industries producer checked 2026-07-30 · link not kept
  2. Custom biogenic systems producer checked 2024-07-26 · link not kept
  3. Cryoport producer checked 2025-05-13 · link not kept
  4. Worthington industries producer checked 2026-08-03 · link not kept